Brain and Central Nervous System Tumors Clinical Trial
Official title:
San Francisco Bay Area Adult Glioma Prognosis Study Protocol
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory
may help doctors learn more about changes that occur in DNA and identify biomarkers related
to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at blood and cheek cell samples from patients with
glioma.
OBJECTIVES:
Primary
- Determine factors related to glioma survival in patients from two population-based case
series collected in the San Francisco Bay Area between August 1991 and April 1994
(series 1) and May 1997 and August 1999 (series 2).
Secondary
- Determine vital status for 879 patients in the two San Francisco Bay Area
population-based series through July 2004.
- Determine survival as a function of established, potential, and yet unstudied prognostic
indicators.
- Gather data to validate results from this study with information from adult glioma
patients enrolled prospectively at the UCSF-Neuro-Oncology clinic and through series 3
of the San Francisco Bay Area Adult Glioma Study; incorporate results from this study
and other components of the SPORE into ongoing clinical investigations at the Brain
Tumor Research Center and Neuro-Oncology Service at UCSF.
- Using funding from the organization Accelerate Brain Cancer Cure (ABC2), genotype
several thousand single nucleotide polymorphisms (SNPs) from some study participants;
assess these SNPs for potential relationship to glioma survival.
OUTLINE: Medical records of patients registered to the California Cancer Registry or the
Northern California Cancer Center SEER are reviewed for mortality and treatment information
related to the brain tumor. Blood and buccal specimens are collected from patients with newly
diagnosed disease who are being seen at the UCSF Neuro-Oncology Service. The specimens are
used for polymorphism and tumor marker studies and other pertinent data. Tumor specimens and
treatment information related to the brain tumor are also collected from the SPORE Tissue
Core.
Additional tumor makers are studied, including: chromosome 1p/19q, 7q studies; DNA repair and
oxidative metabolism polymorphisms; and up to 2 tumor markers and 2 constitutive genotyping
studies.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
| Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
| Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
| Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
| Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
| Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
| Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
| Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
| Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
| Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
| Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
| Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
| Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
| Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
| Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
| Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 |